Restore Vision

  • Biotech or pharma, therapeutic R&D
  • Academic, tech transfer

Restore Vision is a clinical-stage biotech company developing RV-001, the world’s first enzyme-based optogenetic gene therapy for inherited retinal diseases. Using a proprietary chimeric rhodopsin delivered to ON-bipolar cells, RV-001 mimics natural phototransduction and offers a gene-independent approach to restoring vision.

Address

Tokyo
Japan

Website

http://restore-vis.com/

Contact Exhibitor


Loading
View all Partnering Companies

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS